ORYZON presents final data on the Phase I trial with ORY-2001 at the Alzheimer’s Association International Conference (AAIC-2017)

BARCELONA, SPAIN and CAMBRIDGE MA.

• Excellent safety data profile on 106 healthy volunteers
• The molecule is brain penetrant
• Data allows establishment of a safe administration scheme for long term efficacy studies

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, presented last week final data on the First in Human clinical trial of ORY-2001 at the Alzheimer’s Association International Conference (AAIC-2017), which took place from 16 to 20 July in London (United Kingdom). Oryzon’s communication, on poster session S8, was entitled “First-in-Human Phase I Results Show Safety, Tolerability and Brain Penetrance of ORY-2001, an Epigenetic Drug Targeting LSD1 and MAO-B” and was presented by Dr. Tamara Maes, Chief Scientific Officer, and Dr. Roger Bullock, Chief Medical Officer of the company.

Click here to see the full Press Release